Lepu Biopharma Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

SciClone Pharmaceuticals (Holdings) Ltd.

Beijing Tong Ren Tang Chinese Medicine Co., Ltd.

Livzon Pharmaceutical Group, Inc.

Luye Pharma Group Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Pharmaceuticals Holding Co., Ltd.

Shandong Boan Biotechnology Co., Ltd.

RemeGen Co., Ltd.

Everest Medicines Ltd.

InnoCare Pharma Ltd.

Lepu Biopharma Co., Ltd.

Why is Lepu Biopharma Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

Poor long term growth as Net Sales has grown by an annual rate of 6.34% and Operating profit at 12.64% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 44.44%, its profits have risen by 26.6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Lepu Biopharma Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Lepu Biopharma Co., Ltd.

-100.0%

0.54

74.96%

Hang Seng Hong Kong

8.25%

0.36

24.71%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.34%

EBIT Growth (5y)

12.64%

EBIT to Interest (avg)

-2.72

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.52

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

19.22

EV to EBIT

-6562.55

EV to EBITDA

-7104.01

EV to Capital Employed

13.01

EV to Sales

14764.26

PEG Ratio

Dividend Yield

ROCE (Latest)

-0.20%

ROE (Latest)

-0.22%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -34.53% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 18.16 times

NET SALES(Q)

Highest at HKD 500.49 MM

OPERATING PROFIT(Q)

Highest at HKD 139.87 MM

OPERATING PROFIT MARGIN(Q)

Highest at 27.95 %

PRE-TAX PROFIT(Q)

Highest at HKD 56.39 MM

NET PROFIT(Q)

Highest at HKD 63.05 MM

-6What is not working for the Company

INTEREST(HY)

At HKD 16.03 MM has Grown at 74.8%

Here's what is working for Lepu Biopharma Co., Ltd.

Net Sales

At HKD 500.49 MM has Grown at 246.53%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (HKD MM)

Pre-Tax Profit

At HKD 56.39 MM has Grown at 127.41%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (HKD MM)

Net Profit

At HKD 63.05 MM has Grown at 130.26%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (HKD MM)

Net Sales

Highest at HKD 500.49 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Operating Profit

Highest at HKD 139.87 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at 27.95 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at HKD 56.39 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

Highest at HKD 63.05 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

Debtors Turnover Ratio

Highest at 18.16 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -34.53% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Lepu Biopharma Co., Ltd.

Interest

At HKD 16.03 MM has Grown at 74.8%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)